856165-70-3Relevant academic research and scientific papers
TRIAZOLE OXADIAZOLES DERIVATIVES
-
Page/Page column 100, (2009/07/25)
The invention relates to compounds of formula (I), wherein R1, R2, Ra, Rb, X have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.
Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes
Yan, Lin,Huo, Pei,Doherty, George,Toth, Lesile,Hale, Jeffrey J.,Mills, Sander G.,Hajdu, Richard,Keohane, Carol A.,Rosenbach, Mark J.,Milligan, James A.,Shei, Gan-Ju,Chrebet, Gary,Bergstrom, James,Card, Deborah,Quackenbush, Elizabeth,Wickham, Alexandra,Mandala, Suzanne M.
, p. 3679 - 3683 (2007/10/03)
A series of 3-arylpropionic acids were synthesized as S1P1 receptor agonists. Structure-activity relationship studies on the pendant phenyl ring revealed several structural features offering selectivity of S1P1 binding against S1Psu
(3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES AS S1P (EDG) RECEPTOR AGONISTS
-
Page/Page column 42, (2008/06/13)
The present invention encompasses compounds of Formula A: A as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.
